Tadalafil Patent History and Generic Timeline

How Tadalafil Works: PDE5 Inhibition in Brief

Tadalafil is a selective phosphodiesterase type 5 (PDE5) inhibitor that blocks the degradation of cyclic guanosine monophosphate (cGMP) in vascular smooth muscle. The result is prolonged nitric oxide-mediated vasodilation in the corpus cavernosum, producing erections when combined with sexual stimulation. What sets tadalafil apart from sildenafil and vardenafil is its 17.5-hour terminal half-life, which supports both on-demand use at 10 to 20 mg and once-daily dosing at 2.5 to 5 mg 1.

Brock et al. demonstrated in a 12-week, randomized, double-blind trial (N=348) that tadalafil 10 mg and 20 mg significantly improved erectile function domain scores on the IIEF versus placebo, with efficacy documented as early as 30 minutes and lasting up to 36 hours post-dose 1. That prolonged window became the drug's primary commercial differentiator and is the reason daily low-dose tadalafil gained a second FDA indication for benign prostatic hyperplasia (BPH) with or without concurrent ED in October 2011.

The dual ED-BPH indication mattered enormously for Lilly's patent strategy. It gave the company grounds to seek additional method-of-use patents, which extended commercial protection beyond the original compound claim.

The Original Patent Portfolio

Lilly's exclusivity rested on a layered set of patents, not a single filing. The core compound patent, US 5,859,006 (the '006 patent), was filed in 1994 and covered tadalafil itself as a chemical entity. It was set to expire in 2016 but received a pediatric exclusivity extension of six months, pushing the effective expiry to November 2017.

Surrounding that compound claim, Lilly held several secondary patents. US 7,771,768 covered a specific crystalline polymorph (Form I) of tadalafil used in commercial tablets. That patent expired in September 2016. US 6,821,975 and US 7,070,801 covered methods of treating sexual dysfunction using tadalafil at specified doses, with expiration dates in 2016 to 2019 2.

A separate cluster of patents addressed the daily-dose BPH indication. US 8,273,720 and related filings covered the method of treating lower urinary tract symptoms (LUTS) secondary to BPH with 2.5 to 5 mg tadalafil once daily. These later patents did not expire until 2020 and became the primary battleground in Paragraph IV litigation 3.

Understanding this layering matters for one reason: generic entry did not hinge on a single date. It required either waiting out every listed patent or successfully challenging them.

Paragraph IV Challenges and Hatch-Waxman Litigation

The Hatch-Waxman Act allows generic manufacturers to file abbreviated new drug applications (ANDAs) with a Paragraph IV certification, asserting that the brand's listed patents are either invalid or will not be infringed by the proposed generic product. Multiple companies filed such certifications against Lilly's tadalafil patents beginning in 2013.

Mylan filed the first Paragraph IV ANDA for tadalafil. Teva, Aurobindo, Torrent, and others followed. Lilly responded with infringement suits, triggering a 30-month stay that blocked FDA approval of the generics while litigation proceeded 4.

The litigation centered on two main questions. First, whether the polymorph patent (US 7,771,768) was valid given prior art showing the same crystalline form. Second, whether the daily-dose BPH method-of-use patents could block generics that only sought approval for ED. Courts in the Eastern District of Virginia and the District of Delaware handled the bulk of these cases between 2014 and 2016.

Rather than a full trial verdict on every patent, Lilly reached settlement agreements with multiple generic firms. The standard settlement structure allowed generic launches beginning September 2018, roughly 10 months after the compound patent expired. This pattern, brand settlements that allow "authorized generic" or first-filer entry on a negotiated date, is common in the PDE5 inhibitor class.

Mylan obtained first-filer exclusivity (180-day Hatch-Waxman exclusivity) for certain strengths. That 180-day window meant other ANDA holders had to wait until early 2019 to launch, unless they had their own separate settlement dates.

The 2018 Generic Launch and Market Entry Sequence

On September 27, 2018, Lilly itself launched an "authorized generic" version of Cialis through a partnership arrangement, pricing it at roughly half the brand cost 5. The same week, Mylan's AB-rated generic tadalafil hit pharmacy shelves.

Within six months, Teva, Aurobindo, Ajanta, Torrent, Lupin, and Amneal had all entered the market. Price erosion was steep. Brand Cialis had averaged $370 to $450 for thirty 5 mg tablets; by mid-2019, generic 5 mg tadalafil was available for under $30 for the same quantity at major chain pharmacies. That is a reduction exceeding 90%.

By Q4 2019, generic tadalafil accounted for more than 85% of all tadalafil prescriptions dispensed in the United States, according to IQVIA data. That share has continued to climb. Current estimates place generic penetration above 95%.

The FDA's Orange Book now lists over 20 approved ANDA products for tadalafil across 2.5 mg, 5 mg, 10 mg, and 20 mg strengths, all rated AB (therapeutically equivalent) to the Cialis reference listed drug 5.

How Generic Tadalafil Compares to Brand Cialis

The FDA's AB rating means that each approved generic tadalafil product has demonstrated bioequivalence to Cialis in a crossover pharmacokinetic study, with the 90% confidence interval for Cmax and AUC falling within the 80% to 125% acceptance range. In clinical terms, a patient switching from brand Cialis 5 mg daily to any AB-rated generic tadalafil 5 mg should expect the same steady-state plasma concentrations and the same clinical effect 6.

Some patients report subjective differences after switching. Excipients (binders, fillers, coatings) can vary between manufacturers, and this occasionally affects GI tolerability or dissolution speed. However, no published head-to-head trial has demonstrated a statistically significant difference in efficacy or safety between brand and generic tadalafil. The Endocrine Society and the American Urological Association do not distinguish between brand and generic PDE5 inhibitors in their treatment guidelines 7.

One practical difference: brand Cialis is a yellow, almond-shaped film-coated tablet. Generic versions come in various shapes and colors depending on the manufacturer. This cosmetic variation has no pharmacological significance but can cause confusion for patients who associate pill appearance with efficacy.

Daily-Dose Tadalafil for BPH: Patent Nuances

The daily 5 mg tadalafil indication for BPH-LUTS deserves separate attention because its patent situation was distinct from the ED indication. Lilly's BPH method-of-use patents (US 8,273,720 and related filings) did not expire until 2020. Some generic manufacturers initially launched with labeling that "carved out" the BPH indication, meaning their FDA-approved label only mentioned ED, not BPH 8.

This is known as a "section viii" or skinny-label strategy under 21 CFR 314.94(a)(8)(iv). The generic label omits the patented indication while still covering the unpatented one. Physicians could (and did) prescribe skinny-label generic tadalafil off-label for BPH, but the manufacturer's labeling did not reference that use.

After the BPH method-of-use patents expired in 2020, generic manufacturers updated their labels to include the full range of indications: ED on-demand, ED daily, and BPH-LUTS. Today, all major generic tadalafil products carry the same indication set as brand Cialis.

The LUTS-BPH data supporting this indication came from trials showing that tadalafil 5 mg daily improved International Prostate Symptom Score (IPSS) by 4.9 points versus 2.3 for placebo over 12 weeks, with concurrent improvements in erectile function 3. That dual benefit remains a reason clinicians choose tadalafil over tamsulosin or other alpha-blockers in men with both conditions.

Current Pricing and Access in 2026

Generic tadalafil is now one of the most affordable branded-to-generic conversions in the prescription drug market. Cash prices at major U.S. pharmacies in 2026 range from approximately $0.30 per tablet for 5 mg (90-count fills via discount programs) to $1.50 per tablet for 20 mg at pharmacies without discount pricing.

Insurance coverage varies. Most commercial plans and Medicare Part D formularies list generic tadalafil on Tier 1 or Tier 2 with copays of $0 to $15 for a 30-day supply. Some plans still impose prior authorization for daily-use tadalafil (2.5 or 5 mg) to confirm a BPH diagnosis, while on-demand use (10 or 20 mg) may face quantity limits of 6 to 12 tablets per month 9.

GoodRx, Cost Plus Drugs (Mark Cuban's pharmacy), and Amazon Pharmacy have driven further price compression. As of May 2026, Cost Plus Drugs lists tadalafil 5 mg at $0.17 per tablet plus a flat dispensing fee. This makes daily tadalafil therapy for combined ED and BPH cost-competitive with over-the-counter supplements that have no proven efficacy.

Dr. Mohit Khera, professor of urology at Baylor College of Medicine, has noted: "The availability of generic tadalafil has fundamentally changed how we approach ED and BPH management. Cost is no longer a barrier to daily PDE5 inhibitor therapy for the vast majority of patients."

A second expert perspective comes from the American Urological Association's 2023 ED guideline update, which states: "Generic PDE5 inhibitors should be considered first-line pharmacotherapy for ED, and daily tadalafil is a reasonable option for men with concurrent LUTS-BPH" 7.

International Generic Availability

Outside the United States, generic tadalafil timelines varied based on national patent law. In the European Union, the compound patent expired in November 2017 (aligned with the U.S.), and multiple generics launched across EU member states in late 2017 and early 2018. The UK saw generic tadalafil from Accord, Mylan, and Actavis by December 2017 10.

India never granted a compound patent on tadalafil, so Indian manufacturers (Cipla, Sun Pharma, Ajanta) have produced generic versions since the early 2000s. These Indian generics are exported to over 100 countries and formed the basis for many of the ANDA filings that eventually entered the U.S. market.

Canada approved generic tadalafil in 2018, with Apotex and Teva among the first entrants. Australia's Pharmaceutical Benefits Scheme listed generic tadalafil in 2019.

Japan represents an outlier: Lilly maintained stronger patent protection there through supplementary patent certificates, and the first Japanese generics did not appear until April 2020.

What Remains Patent-Protected

As of 2026, no active composition-of-matter or polymorph patents cover tadalafil itself. All method-of-use patents for ED and BPH have also expired. The only remaining patent activity involves specific formulation technologies (extended-release matrices, orally disintegrating tablet designs) held by individual generic companies, not by Lilly 5.

Lilly retains the Cialis trademark and still markets branded Cialis in some international markets, but the company's financial reports show that Cialis revenue dropped from $2.3 billion in 2017 (its last full year of exclusivity) to under $150 million by 2020, almost entirely from international markets where generic entry was delayed.

No new Orange Book-listed patents have been added to NDA 021368 since 2020. Barring a novel formulation filing by a third party, generic tadalafil's competitive market will remain fully open for the foreseeable future.